THE CRUNCH
Enveda has raised $311 million in funding, valuing the AI biotech at $2 billion. The company is using artificial intelligence to discover drugs from nature, with a focus on treatments for skin conditions and therapies to maintain weight loss after stopping GLP-1s.


